Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lower Blood Pressure Target and Reduced Norepinephrine in Cardiogenic Shock After Myocardial Infarction
2021-005551-36Phase 4Active
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of norepinephrine in cardiogenic shock (2 arms). Primary endpoint: Composite of all-cause mortality and severe renal failure requiring renal replacement therapy within 30 days. Started Apr 2022; status: active.
02
Drugs
norepinephrine
03
Conditions
cardiogenic shock
Beyond the preview
Go deeper on 2021-005551-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005551-36.